I as a systemic treatment of a patient with metastatic thyroid cancer was first reported in 1948
1 . This agent has subsequently become firmly established as part of the treatment of high-risk thyroid cancer and especially for metastatic disease. There has been an evolution in the quality of assessment of the distribution of radioactive iodine (RAI) within the body, progressing from Geiger-Muller counting to imaging; first with the rectilinear scanning and then with the gamma camera. This "dual tracer" approach seems to address most cases of differentiated thyroid cancer. Ga-DOTATATE) in this disease. Hurthle cell carcinoma has been previously reported as having increased SSTR expression, comprising the majority of cases in a previous small series treated with peptide receptor radionuclide therapy (PRRT) 18 . While localisation of disease in 33% of cases in the current study provides the opportunity for additional local therapy, the relatively modest intensity of uptake identified within this small series (mean SUVmax 4.8, range 3.0-10.1) suggests that only a minority of cases will demonstrate sufficient uptake to enable PRRT.
Whilst it is not uncommon for poorly differentiated or oncocytic thyroid cancer to be non- Ga-DOTATOC in the 73 non-iodine avid cohort. This makes the findings of the current study even more unusual.
In addition to a need to verify these findings in larger prospective studies, it will be important to better understand the biological basis for SSTR expression in the thyroid and its role in cell signalling. This study certainly broadens the potential role of 68 Ga-DOTATOC PET/CT to include cases of thyroid cancer with elevated Tg despite negative RAI and FDG PET/CT. It also provides a unique opportunity to review the current role of molecular imaging in advanced thyroid cancer, and outline a new theranostic paradigm incorporating SSTR imaging for this heterogeneous disease (Figure 1 ).
